MedTrace Logo

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2016-03-22

Study results available
· View outcomes & findings →

Summary

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

Conditions

  • Alopecia
  • Alopecia, Androgenetic
  • Baldness

Interventions

DRUG

Bimatoprost Solution 1

Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

DRUG

Bimatoprost Solution 2

Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

DRUG

Bimatoprost Vehicle

Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-09-30
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01904721 on ClinicalTrials.gov